LabCorp, the mammoth medical investigations company, is still recuperating from a major ransomware attack and, almost a week later, won’t reveal how the hackers got entry nor the number of servers that were hit.
Pharmaceutical giant AstraZeneca and integrated health services provider Geisinger are partnering to create an app suite, which by connecting to electronic health records (EHR) aims to upgrade asthma care.
UK-based medical device manufacturer, Lumendi obtained the European CE-Mark for its DiLumen Endolumenal Interventional Platform (EIP) which is used as an endoscope accessory.
Artificial intelligence based company Viz.ai, currently developing software for the detection of urgent stroke cases, has recently raised $21 million in venture capital to develop its portfolio.
One of the largest clinical laboratories in the U.S, LabCorp Diagnostics of North Carolina faced a security breach by hackers forcing it to shut down on Sunday to combat the cyber attack.
K, a new free primary care app was launched by the individualized health information company, K Health. The app’s AI scours through the history of diagnoses and treatments to provide the user with the most likely treatment of their condition and can simultaneously connect them to a network of primary health care providers.
A five-year engineering pact between Walmart and Microsoft was signed on Tuesday to clash with Amazon in the AI, cloud computing and retail sectors.
Bright.md announced a merger with Vancouver-based MyCare MedTech this week for an innovative customer deployment, setting foot into the global marketplace.
Johnson & Johnson is moving out from the diabetes business and sold its Calibra product (marketed as OneTouch Via, but never launched) to a 10-year-old company named CeQur, which was already working on a similar insulin-delivery wearable. The terms and conditions of this deal have not yet been yet disclosed, but CeQur has attained an exclusive worldwide license for this technology.
Spero Therapeutics granted $15.7 million for research on SPR994, its oral carbapenem-class candidate, to study the drug’s efficacy against biological threats like anthrax, plague and melioidosis as a part of an interagency collaboration.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.